Showing 11,981 - 12,000 results of 60,794 for search '(( 50 ((ns decrease) OR (a decrease)) ) OR ( 5 ((we decrease) OR (nn decrease)) ))', query time: 1.34s Refine Results
  1. 11981
  2. 11982

    Cold-Burst Method for Nanoparticle Formation with Natural Triglyceride Oils by Diana Cholakova (2897222)

    Published 2021
    “…Mean drop diameters of ca. 50–100 nm were achieved with some of the studied oils. …”
  3. 11983

    Cold-Burst Method for Nanoparticle Formation with Natural Triglyceride Oils by Diana Cholakova (2897222)

    Published 2021
    “…Mean drop diameters of ca. 50–100 nm were achieved with some of the studied oils. …”
  4. 11984

    Cold-Burst Method for Nanoparticle Formation with Natural Triglyceride Oils by Diana Cholakova (2897222)

    Published 2021
    “…Mean drop diameters of ca. 50–100 nm were achieved with some of the studied oils. …”
  5. 11985
  6. 11986
  7. 11987
  8. 11988
  9. 11989

    CD8 and CD4 Epitope Predictions in RV144: No Strong Evidence of a T-Cell Driven Sieve Effect in HIV-1 Breakthrough Sequences from Trial Participants by Kalpana Dommaraju (650755)

    Published 2014
    “…Comparisons between the vaccine and placebo arm did not reveal robust evidence for a T cell driven sieve effect, although some differences were noted in Env-V2 (0.022≤p-value≤0.231). The paucity of CD8 T cell responses identified following RV144 vaccination, with no evidence for V2 specificity, considered together both with the association of decreased infection risk in RV 144 participants with V-specific antibody responses and a V2 sieve effect, lead us to hypothesize that this sieve effect was not T cell specific. …”
  10. 11990
  11. 11991

    Data_Sheet_2_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

    Published 2023
    “…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”
  12. 11992

    Data_Sheet_1_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

    Published 2023
    “…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”
  13. 11993

    Data_Sheet_3_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

    Published 2023
    “…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”
  14. 11994

    Data_Sheet_4_Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network... by Fen Cao (4496014)

    Published 2023
    “…To compare the effectiveness and safety of endothelin receptor antagonists (ERAs), phosphodiesterase type 5 Inhibitors (PDE-5i), and prostaglandins (ProA) in the treatment of pediatric PAH, we investigated six hemodynamic parameters, four respiratory parameters, intensive care unit (ICU) stay duration, length of hospital stay, and two safety outcomes.…”
  15. 11995
  16. 11996
  17. 11997
  18. 11998

    Early and late pulmonary effects of nebulized LPS in mice: An acute lung injury model by Natália de Souza Xavier Costa (4474648)

    Published 2017
    “…</p><p>Results</p><p>The LPS 24h group showed increased pro-inflammatory cytokine levels, intense cell influx, increased total septal volume, septal thickening and decreased surface density of the alveolar septa. The LPS 5w group showed persistent lung inflammation, septal thickening, increased total lung volume, accentuated collagen deposition, especially of collagen type I, and decreased MMP-2 protein expression.…”
  19. 11999

    Schematic overview of molecular processes altered during disease progression in the SN of PD, identified using transcriptome analysis. by Anke A. Dijkstra (756877)

    Published 2015
    “…In addition, we observed down regulation of mRNA levels of the upstream regulators in mTOR pathway. …”
  20. 12000

    Effectiveness of a Randomized Controlled Lifestyle Intervention to Prevent Obesity among Chinese Primary School Students: CLICK-Obesity Study by Fei Xu (368913)

    Published 2015
    “…Compared with the control group, the intervention group was more likely to decrease their BMI (OR = 1.44, 95%CI = 1.10, 1.87) by 0.5 kg/m<sup>2</sup> or above, increase the frequency of jogging/running (OR = 1.55, 95%CI = 1.18, 2.02), decrease the frequency of TV/computer use (OR = 1.41, 95%CI = 1.09, 1.84) and of red meat consumption (OR = 1.50, 95%CI = 1.15, 1.95), change commuting mode to/from school from sedentary to active mode (OR = 2.24, 95%CI = 1.47, 3.40), and be aware of the harm of selected obesity risk factors.…”